TD Cowen analyst Tara Bancroft raised the firm’s price target on Ocular Therapeutix to $11 from $8 and keeps a Market Perform rating on the shares. The firm said the company is now screening and providing loading doses for the first patients in the SOL-1 wAMD pivotal trial, and KOL’s are optimistic for enrollment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, March 11, 2024
- Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
- Ocular Therapeutix Inc (OCUL) Q4 Earnings Cheat Sheet
- Ocular Therapeutix options imply 8.8% move in share price post-earnings
